Regorafenib, a multitargeted kinase inhibitor, has shown promise in advanced melanoma patients who had previously progressed on anti-PD-1, anti-CTLA-4, and BRAF/MEK inhibitors, 42.8% of BRAFV600 mutation-positive patients treated with regorafenib combined with BRAFi/MEKi showed a partial response, including regression of brain metastases. The gene discussed is CTLA4; the disease is melanoma.